Clinical Trial

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-30; most recent amendment 2024-09-17.
Trial Details
NCT Number NCT04951947
Lead Sponsor Hunan Province Tumor Hospital
Conditions Small-cell Lung Cancer
Enrollment 30 participants
Start Date 2023-06-01
Primary Completion 2024-12-01 (estimated)
Study Completion 2025-06-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19